{"id":765205,"date":"2025-09-25T12:48:02","date_gmt":"2025-09-25T12:48:02","guid":{"rendered":"https:\/\/www.abnewswire.com\/pressreleases\/?p=765205"},"modified":"2025-09-25T12:48:02","modified_gmt":"2025-09-25T12:48:02","slug":"cystinuria-pipeline-2025-innovative-clinical-progress-by-5-global-leaders-delveinsight-highlighting-revive-therapeutics-otsuka-pharmaceutical-eloxx-pharmaceuticals-travere-therapeutics-advic","status":"publish","type":"post","link":"https:\/\/www.abnewswire.com\/pressreleases\/cystinuria-pipeline-2025-innovative-clinical-progress-by-5-global-leaders-delveinsight-highlighting-revive-therapeutics-otsuka-pharmaceutical-eloxx-pharmaceuticals-travere-therapeutics-advic_765205.html","title":{"rendered":"Cystinuria Pipeline 2025: Innovative Clinical Progress by 5+ Global Leaders \u2013 DelveInsight | Highlighting Revive Therapeutics, Otsuka Pharmaceutical, Eloxx Pharmaceuticals, Travere Therapeutics, Advic"},"content":{"rendered":"<div style=\"float:right; width:250px; padding:8px 10px 10px 10px;\">\n<div><a href=\"https:\/\/www.abnewswire.com\/upload\/2025\/09\/1758698276.jpg\" style=\"border:none !important;\" target=\"_blank\" rel=\"nofollow\" ><img loading=\"lazy\" decoding=\"async\" class=\"alignnone size-medium wp-image-29\" title=\"Cystinuria Pipeline 2025: Innovative Clinical Progress by 5+ Global Leaders &ndash; DelveInsight | Highlighting Revive Therapeutics, Otsuka Pharmaceutical, Eloxx Pharmaceuticals, Travere Therapeutics, Advic\" src=\"https:\/\/www.abnewswire.com\/upload\/2025\/09\/1758698276.jpg\" alt=\"Cystinuria Pipeline 2025: Innovative Clinical Progress by 5+ Global Leaders &ndash; DelveInsight | Highlighting Revive Therapeutics, Otsuka Pharmaceutical, Eloxx Pharmaceuticals, Travere Therapeutics, Advic\" width=\"225\" height=\"225\" style=\"padding:0px 0px 10px 10px; border:0 solid !important;\" \/><\/a><\/div>\n<div class=\"quotes\">\n<div>Cystinuria Pipeline 2025  <\/div>\n<\/div>\n<\/div>\n<div style=\"font-style:italic; padding:8px 0px;\">DelveInsight\u2019s, \u201cCystinuria &#8211; Pipeline Insight, 2025,\u201d report provides comprehensive insights about 5+ companies and 5+ pipeline drugs in Cystinuria pipeline landscape. It covers the pipeline drug profiles, including clinical and nonclinical stage products. It also covers the therapeutics assessment by product type, stage, route of administration, and molecule type. It further highlights the inactive pipeline products in this space.<\/div>\n<p style=\"text-align: justify;\">As Cystinuria increasingly impacts populations worldwide and is linked to comorbidities such as diabetes, cardiovascular disease, and certain cancers, there is a rising need for safer and more effective treatment options. DelveInsight reports that the Cystinuria pipeline includes over 5 pharmaceutical and biotech companies actively developing more than 5 therapeutic candidates for the condition. These candidates are at various stages of clinical and preclinical development, reflecting significant innovation and dedication to addressing this important health challenge.<\/p>\n<p style=\"text-align: justify;\">DelveInsight&rsquo;s &ldquo;Cystinuria Pipeline Insight 2025&rdquo; offers a comprehensive strategic analysis of the R&amp;D landscape, including clinical trial progress, emerging therapies, mechanisms of action, competitive positioning, and key company initiatives. The report serves as a vital resource for researchers, healthcare investors, and decision-makers seeking insights into the evolving Cystinuria therapeutics market and the breakthroughs shaping its future.<\/p>\n<p style=\"text-align: justify;\"><strong>Explore the Cutting-Edge Landscape of <a rel=\"nofollow\" href=\"https:\/\/www.delveinsight.com\/report-store\/cystinuria-pipeline-insight?utm_source=abnewswire&amp;utm_medium=market&amp;utm_campaign=kpr\">Cystinuria Drug Development<\/a><\/strong><\/p>\n<p style=\"text-align: justify;\"><strong>Key Takeaways from the Cystinuria Pipeline Report<\/strong><\/p>\n<ul style=\"text-align: justify;\">\n<li>\n<p>DelveInsight&rsquo;s Cystinuria pipeline report highlights an active therapeutic landscape with over 5 companies developing more than 5 pipeline candidates for Cystinuria treatment.<\/p>\n<\/li>\n<li>\n<p>ADV7103 is currently being assessed in the Phase 2\/3 CORAL-1 trial, which is enrolling Cystinuria patients across sites in France and Belgium, with primary study completion anticipated in May 2025. In May 2024, the FDA approved tiopronin delayed-release tablets for patients aged 9 years and older who do not respond to standard therapies.<\/p>\n<\/li>\n<li>\n<p>Cycle Pharmaceuticals, in collaboration with Torrent Pharma Inc., launched VENXXIVA&trade; (tiopronin) delayed-release tablets in the U.S. in March 2025. This formulation offers flexible dosing and is supported by patient assistance programs under Cycle Vita&trade;. Additionally, in March 2024, ADV7103 received Orphan Drug Designation from the FDA, incentivizing the development of treatments for rare diseases by providing benefits such as market exclusivity upon approval.<\/p>\n<\/li>\n<li>\n<p>Key Cystinuria players including Revive Therapeutics, Otsuka Pharmaceutical, Eloxx Pharmaceuticals, Travere Therapeutics, Advicenne, and others, are actively exploring new therapies to enhance the Cystinuria treatment landscape. Promising pipeline candidates include Bucillamine and several others.<\/p>\n<\/li>\n<\/ul>\n<p style=\"text-align: justify;\"><strong>Cystinuria Overview:<\/strong><\/p>\n<p style=\"text-align: justify;\">Cystinuria is a hereditary metabolic disorder in which the kidneys excrete excessive amounts of cystine and related amino acids&mdash;lysine, arginine, and ornithine&mdash;into the urine. Since cystine has low solubility, it can form crystals or kidney stones, although not all individuals with the condition develop stones. The disorder results from mutations in the SLC3A1 or SLC7A9 genes, which impair normal amino acid transport in the kidneys. It is inherited in an autosomal recessive manner, requiring two defective gene copies for symptoms to manifest. Carriers typically remain asymptomatic but may have slightly elevated cystine levels in their urine.<\/p>\n<p style=\"text-align: justify;\"><strong>Download the Cystinuria sample report to know in detail about the Cystinuria treatment market @ <a rel=\"nofollow\" href=\"https:\/\/www.delveinsight.com\/sample-request\/cystinuria-pipeline-insight?utm_source=abnewswire&amp;utm_medium=market&amp;utm_campaign=kpr\">https:\/\/www.delveinsight.com\/sample-request\/cystinuria-pipeline-insight?utm_source=abnewswire&amp;utm_medium=market&amp;utm_campaign=kpr<\/a><\/strong><\/p>\n<p style=\"text-align: justify;\"><strong>Cystinuria Pipeline Analysis<\/strong><\/p>\n<p style=\"text-align: justify;\">The Cystinuria pipeline insights report 2025, provides insights into:<\/p>\n<ul style=\"text-align: justify;\">\n<li>\n<p>Provides comprehensive insights into key companies developing therapies in the Cystinuria Market.<\/p>\n<\/li>\n<li>\n<p>Categorizes Cystinuria therapeutic companies by development stage: early, mid, and late-stage.<\/p>\n<\/li>\n<li>\n<p>Highlights major companies involved in targeted therapy development, including both active and inactive (paused\/discontinued) projects.<\/p>\n<\/li>\n<li>\n<p>Reviews emerging Cystinuria drugs under development based on:<\/p>\n<ul>\n<li>\n<p>Stage of development<\/p>\n<\/li>\n<li>\n<p>Cystinuria Route of administration<\/p>\n<\/li>\n<li>\n<p>Target receptor<\/p>\n<\/li>\n<li>\n<p>Monotherapy vs. combination therapy<\/p>\n<\/li>\n<li>\n<p>Cystinuria Mechanism of action<\/p>\n<\/li>\n<li>\n<p>Molecular type<\/p>\n<\/li>\n<\/ul>\n<\/li>\n<li>\n<p>Offers detailed analysis of:<\/p>\n<ul>\n<li>\n<p>Company-to-company and company-academia collaborations<\/p>\n<\/li>\n<li>\n<p>Cystinuria Licensing agreements<\/p>\n<\/li>\n<li>\n<p>Funding and investment activities supporting future Cystinuria market advancement.<\/p>\n<\/li>\n<\/ul>\n<\/li>\n<\/ul>\n<p style=\"text-align: justify;\"><strong>Unlock key insights into emerging Cystinuria therapies and market strategies here: <a rel=\"nofollow\" href=\"https:\/\/www.delveinsight.com\/report-store\/cystinuria-pipeline-insight?utm_source=abnewswire&amp;utm_medium=market&amp;utm_campaign=kpr\">https:\/\/www.delveinsight.com\/report-store\/cystinuria-pipeline-insight?utm_source=abnewswire&amp;utm_medium=market&amp;utm_campaign=kpr<\/a><\/strong><\/p>\n<p style=\"text-align: justify;\"><strong>Cystinuria Emerging Drugs<\/strong><\/p>\n<p style=\"text-align: justify;\"><strong>Bucillamine: Revive Therapeutics<\/strong><\/p>\n<p style=\"text-align: justify;\">Bucillamine, a cysteine-derived medication long used in Japan and South Korea for rheumatoid arthritis, is now being evaluated in Phase 2 trials for cystinuria. The drug features two thiol groups and has demonstrated greater efficacy than NAC in replenishing glutathione levels, highlighting its potential to protect against lung damage during infections such as influenza.<\/p>\n<p style=\"text-align: justify;\"><strong>Cystinuria Pipeline Therapeutic Assessment<\/strong><\/p>\n<p style=\"text-align: justify;\"><strong>Cystinuria Assessment by Product Type<\/strong><\/p>\n<p style=\"text-align: justify;\">&bull; Mono<\/p>\n<p style=\"text-align: justify;\">&bull; Combination<\/p>\n<p style=\"text-align: justify;\">&bull; Mono\/Combination<\/p>\n<p style=\"text-align: justify;\"><strong>Cystinuria By Stage<\/strong><\/p>\n<p style=\"text-align: justify;\">&bull; Late-stage products (Phase III)<\/p>\n<p style=\"text-align: justify;\">&bull; Mid-stage products (Phase II)<\/p>\n<p style=\"text-align: justify;\">&bull; Early-stage product (Phase I) along with the details of<\/p>\n<p style=\"text-align: justify;\">&bull; Pre-clinical and Discovery stage candidates<\/p>\n<p style=\"text-align: justify;\">&bull; Discontinued &amp; Inactive candidates<\/p>\n<p style=\"text-align: justify;\"><strong>Cystinuria Assessment by Route of Administration<\/strong><\/p>\n<p style=\"text-align: justify;\">&bull; Oral<\/p>\n<p style=\"text-align: justify;\">&bull; Parenteral<\/p>\n<p style=\"text-align: justify;\">&bull; Intravenous<\/p>\n<p style=\"text-align: justify;\">&bull; Subcutaneous<\/p>\n<p style=\"text-align: justify;\">&bull; Topical<\/p>\n<p style=\"text-align: justify;\"><strong>Cystinuria Assessment by Molecule Type<\/strong><\/p>\n<p style=\"text-align: justify;\">&bull; Recombinant fusion proteins<\/p>\n<p style=\"text-align: justify;\">&bull; Small molecule<\/p>\n<p style=\"text-align: justify;\">&bull; Monoclonal antibody<\/p>\n<p style=\"text-align: justify;\">&bull; Peptide<\/p>\n<p style=\"text-align: justify;\">&bull; Polymer<\/p>\n<p style=\"text-align: justify;\">&bull; Gene therapy<\/p>\n<p style=\"text-align: justify;\"><strong>Download sample pages to get an in-depth assessment of the emerging Cystinuria therapies and <a rel=\"nofollow\" href=\"https:\/\/www.delveinsight.com\/sample-request\/cystinuria-pipeline-insight?utm_source=abnewswire&amp;utm_medium=market&amp;utm_campaign=kpr\">key Cystinuria companies<\/a><\/strong><\/p>\n<p style=\"text-align: justify;\"><strong>Table of Contents<\/strong><\/p>\n<p style=\"text-align: justify;\">1. Report Introduction<\/p>\n<p style=\"text-align: justify;\">2. Executive Summary<\/p>\n<p style=\"text-align: justify;\">3. Cystinuria Current Treatment Patterns<\/p>\n<p style=\"text-align: justify;\">5. Cystinuria &#8211; DelveInsight&#8217;s Analytical Perspective<\/p>\n<p style=\"text-align: justify;\">5. Therapeutic Assessment<\/p>\n<p style=\"text-align: justify;\">5. Cystinuria Late-Stage Products (Phase-III)<\/p>\n<p style=\"text-align: justify;\">7. Cystinuria Mid-Stage Products (Phase-II)<\/p>\n<p style=\"text-align: justify;\">8. Early Stage Products (Phase-I)<\/p>\n<p style=\"text-align: justify;\">9. Pre-clinical Products and Discovery Stage Products<\/p>\n<p style=\"text-align: justify;\">10. Inactive Products<\/p>\n<p style=\"text-align: justify;\">11. Dormant Products<\/p>\n<p style=\"text-align: justify;\">12. Cystinuria Discontinued Products<\/p>\n<p style=\"text-align: justify;\">13. Cystinuria Product Profiles<\/p>\n<p style=\"text-align: justify;\">15. Cystinuria Key Companies<\/p>\n<p style=\"text-align: justify;\">15. Cystinuria Key Products<\/p>\n<p style=\"text-align: justify;\">15. Dormant and Discontinued Products<\/p>\n<p style=\"text-align: justify;\">17. Cystinuria Unmet Needs<\/p>\n<p style=\"text-align: justify;\">18. Cystinuria Future Perspectives<\/p>\n<p style=\"text-align: justify;\">19. Cystinuria Analyst Review<\/p>\n<p style=\"text-align: justify;\">20. Appendix<\/p>\n<p style=\"text-align: justify;\">21. Report Methodology<\/p>\n<p style=\"text-align: justify;\"><strong>Request the sample PDF to get detailed insights about the <a rel=\"nofollow\" href=\"https:\/\/www.delveinsight.com\/report-store\/cystinuria-pipeline-insight?utm_source=abnewswire&amp;utm_medium=market&amp;utm_campaign=kpr\">Cystinuria pipeline reports offerings<\/a><\/strong><\/p>\n<p style=\"text-align: justify;\"><strong>About DelveInsight<\/strong><\/p>\n<p style=\"text-align: justify;\">DelveInsight is a leading Business Consultant and Market Research firm focused exclusively on life sciences. It supports Pharma companies by providing comprehensive end-to-end solutions to improve their performance.<\/p>\n<p><span style='font-size:18px !important;'>Media Contact<\/span><br \/><strong>Company Name:<\/strong> <a href=\"https:\/\/www.abnewswire.com\/companyname\/delveinsight.com_56431.html\" rel=\"nofollow\">DelveInsight Business Research LLP<\/a><br \/><strong>Contact Person:<\/strong> Kritika Rehani<br \/><strong>Email:<\/strong> <a href=\"https:\/\/www.abnewswire.com\/email_contact_us.php?pr=cystinuria-pipeline-2025-innovative-clinical-progress-by-5-global-leaders-delveinsight-highlighting-revive-therapeutics-otsuka-pharmaceutical-eloxx-pharmaceuticals-travere-therapeutics-advic\" rel=\"nofollow\">Send Email<\/a><br \/><strong>Phone:<\/strong> +14699457679<br \/><strong>Address:<\/strong>304 S. Jones Blvd #2432  <br \/><strong>City:<\/strong> Las Vegas<br \/><strong>State:<\/strong> Nevada<br \/><strong>Country:<\/strong> United States<br \/><strong>Website:<\/strong> <a href=\"https:\/\/www.delveinsight.com\/\" target=\"_blank\" rel=\"nofollow\">https:\/\/www.delveinsight.com\/<\/a><\/p>\n<p><img decoding=\"async\" src=\"https:\/\/www.abnewswire.com\/press_stat.php?pr=cystinuria-pipeline-2025-innovative-clinical-progress-by-5-global-leaders-delveinsight-highlighting-revive-therapeutics-otsuka-pharmaceutical-eloxx-pharmaceuticals-travere-therapeutics-advic\" alt=\"\" width=\"1px\" height=\"1px\" \/><\/p>\n","protected":false},"excerpt":{"rendered":"<p>Cystinuria Pipeline 2025 DelveInsight\u2019s, \u201cCystinuria &#8211; Pipeline Insight, 2025,\u201d report provides comprehensive insights about 5+ companies and 5+ pipeline drugs in Cystinuria pipeline landscape. It covers the pipeline drug profiles, including clinical and nonclinical stage products. It also covers the &hellip; <a href=\"https:\/\/www.abnewswire.com\/pressreleases\/cystinuria-pipeline-2025-innovative-clinical-progress-by-5-global-leaders-delveinsight-highlighting-revive-therapeutics-otsuka-pharmaceutical-eloxx-pharmaceuticals-travere-therapeutics-advic_765205.html\">Continue reading <span class=\"meta-nav\">&rarr;<\/span><\/a><\/p>\n","protected":false},"author":1,"featured_media":0,"comment_status":"closed","ping_status":"closed","sticky":false,"template":"","format":"standard","meta":{"footnotes":""},"categories":[435,405,406,403,404],"tags":[],"class_list":["post-765205","post","type-post","status-publish","format-standard","hentry","category-Europe","category-Health-Medicine","category-Pharmaceuticals-Biotech","category-UK","category-US"],"_links":{"self":[{"href":"https:\/\/www.abnewswire.com\/pressreleases\/wp-json\/wp\/v2\/posts\/765205","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/www.abnewswire.com\/pressreleases\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/www.abnewswire.com\/pressreleases\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/www.abnewswire.com\/pressreleases\/wp-json\/wp\/v2\/users\/1"}],"replies":[{"embeddable":true,"href":"https:\/\/www.abnewswire.com\/pressreleases\/wp-json\/wp\/v2\/comments?post=765205"}],"version-history":[{"count":0,"href":"https:\/\/www.abnewswire.com\/pressreleases\/wp-json\/wp\/v2\/posts\/765205\/revisions"}],"wp:attachment":[{"href":"https:\/\/www.abnewswire.com\/pressreleases\/wp-json\/wp\/v2\/media?parent=765205"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/www.abnewswire.com\/pressreleases\/wp-json\/wp\/v2\/categories?post=765205"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/www.abnewswire.com\/pressreleases\/wp-json\/wp\/v2\/tags?post=765205"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}